Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to determine the dose of imatinib mesylate that is most effective with the
least amount of toxic side effects in treating patients who have advanced cancer and kidney
failure. Imatinib mesylate may stop the growth of cancer cells by stopping the enzyme
necessary for cancer cell growth. Kidney failure may delay the elimination of imatinib
mesylate from the body, which may lead to longer drug exposure and increase toxic side
effects